ClinicalTrials.gg
CompletedNCT06219902Updated May 8, 2024

A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women

A Phase 1 interventional study of Elinzanetant (BAY3427080) and Placebo to elinzanetant in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men and Hot Flashes, sponsored by Bayer. Completed at 1 site in Canada. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by Bayer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing elinzanetant in Hot Flashes — none open to participants now, 1 under way, 1 of them phase 3. elinzanetant · Hot Flashes.

Enrollment
7th of 13
64 · median 64
Started
2024
the only one that year
Phase 1
7 of 13
none open now
Registered
13th of 13
by date
Lead sponsor
13 of 13
Bayer

Among the 13 studies testing elinzanetant in Hot Flashes, this one is the 7th largest by enrollment, is the only one that started in 2024, is one of 7 in phase 1, and was the 13th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing elinzanetant in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About elinzanetant

elinzanetant: first FDA approval 2025 (LYNKUET), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing elinzanetant in Hot Flashes as a file.
02

Study summary

Researchers are looking for a better way to treat vasomotor symptoms (VMS), also known as hot flashes.

Hot flashes are intense and sudden feelings of heat along with sweating and reddening of the skin. These are common for women going through the menopause but can also occur in men. Such symptoms are called VMS and are caused by changes in sex hormone levels.

The study treatment, elinzanetant, is being tested for the treatment of VMS in both men and women. It works by blocking the activity of a substance called neurokinin, which is thought to play a role in starting hot flashes.

Elinzanetant may cause lasting effects like sleepiness and tiredness. Such effects may make driving unsafe.

The main purpose of this study is to learn how elinzanetant affects the ability to drive the next day in healthy women.

For this, researchers will study participants' ability to keep a stable position within their lane while driving on a straight road on a computer-based driving test (also known as a driving simulator).

In this study, participants will take 2 different doses of elinzanetant, another drug called zopiclone, and matching placebos to these drugs.

Zopiclone helps treat sleeping problems. A placebo looks like a study drug but does not have any medicine in it.

Participants will take elinzanetant, zopiclone, and their matching placebos by mouth.

This study will have 4 treatment periods with each period lasting 6 days. In each period, participants will receive one of the following treatments in an order assigned to them randomly (by chance):

  • dose A of elinzanetant and a zopiclone placebo
  • dose B of elinzanetant and a zopiclone placebo
  • zopiclone 7.5 milligrams (mg) and elinzanetant placebo
  • elinzanetant placebo and zopiclone placebo

Each participant will be in the study for around 15 weeks with up to 6 visits to the study site.

Participants will visit the study site:

  • once before the treatment starts, so the study doctors and their team can check on their health and confirm if the participant can join the study
  • once in each of the 4 treatment periods for a 6-day stay at the study site with a gap of 14 days between each period. During each stay, they will take the assigned treatment from Days 1 to 5 and the driving test on Days 2 and 6
  • once, 2 to 3 days after their last treatment so the study doctors and their team can check on their health

During the study, the doctors and their study team will:

  • check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram (ECG)
  • check the participants' ability to drive and their brain function and level of sleepiness using different tests including a driving simulator test
  • check the level of the study drugs in participants' blood
  • ask the participants questions about how they are feeling and what adverse events they are having.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective of whether they think they are related to the study treatment or not.

03

Conditions studied

  • Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
  • Hot Flashes

Browse trials for

Keywords

  • Driving performance,
  • Cognitive function
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females aged 40 to 65 years, inclusive, at signing of .
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, blood pressure, pulse rate and (ECG).
  • Participant has a regular sleep pattern, is not engaged in shift-work, and in general, has at least 7 hours of sleep each night (bedtime occurs between 21:00 and 24:00 hours).
  • Participant possesses a valid driver's license and is an active driver. Drives a minimum of 8,000 kilometers per year for the previous 3 years.

Exclusion criteria

Exclusion Criteria:

  • Relevant diseases within the last 4 weeks prior to the first administration of study intervention, including febrile illness.
  • A history within 2 years of, or current treatment for, a sleeping disorder (including excessive snoring, obstructive sleep apnea), or a chronic painful condition that interferes with the participant's sleep.
  • Abnormal finding in the physical examination, , blood pressure, pulse rate or clinical laboratory results at Screening, that are considered by the investigator.
  • Use of any medication of dietary supplement which may affect central nervous system (CNS) function and may confound the pharmacodynamic assessments of the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Treatment sequences A-C-D-B

    Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).

    Drug: Elinzanetant (BAY3427080) · Drug: Placebo to elinzanetant · Drug: Zopiclone · Drug: Placebo to zopiclone

  • Experimental
    Treatment sequences B-D-C-A

    Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).

    Drug: Elinzanetant (BAY3427080) · Drug: Placebo to elinzanetant · Drug: Zopiclone · Drug: Placebo to zopiclone

  • Experimental
    Treatment sequences C-B-A-D

    Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).

    Drug: Elinzanetant (BAY3427080) · Drug: Placebo to elinzanetant · Drug: Zopiclone · Drug: Placebo to zopiclone

  • Experimental
    Treatment sequences D-A-B-C

    Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).).

    Drug: Elinzanetant (BAY3427080) · Drug: Placebo to elinzanetant · Drug: Zopiclone · Drug: Placebo to zopiclone

Interventions

  • Oral administration of multiple doses of elinzanetant.

  • DrugPlacebo to elinzanetant

    Oral administration

  • Oral administration

  • DrugPlacebo to zopiclone

    Oral administration

06

What researchers measure

Primary outcomes

  1. Simulated driving performance as measured by SDLP using CRCDS-MiniSim

    SDLP: standard deviation of lateral position. CRCDS-MiniSim: Cognitive Research Corporation's Driving Simulator-MiniSim.

    Time frame: Approximately 9 hours after last dose

Secondary outcomes

  1. Lane Exceedance: Number of Exceedance.

    Time frame: Approximately 9 hours after last dose

  2. Lane Exceedance: Maximum Duration of Exceedance.

    Time frame: Approximately 9 hours after last dose

  3. Lane Exceedance: Area of Exceedance.

    Time frame: Approximately 9 hours after last dose

  4. Excessive Speed Count

    Time frame: Approximately 9 hours after last dose

  5. Average Speed and Speed Deviation

    Time frame: Approximately 9 hours after last dose

  6. Driving safety measures: Total number of excessive Ay (cornering speed threshold-exceeded)

    Time frame: Approximately 9 hours after last dose

  7. Driving safety measures: Total number of collisions

    Time frame: Approximately 9 hours after last dose

  8. Divided Attention: Correct responses; Omission Errors; Commission Errors; Reaction Time; Standard Deviation of Reaction Time

    Time frame: Approximately 9 hours after last dose

  9. CogScreen Symbol Digit Coding Test: Number of Correct responses

    CogScreen Symbol Digit Coding test is a computer analogue of the conventional digit symbol-substitution task found in the revised Wechsler intelligence scales.

    Time frame: Approximately 9 hours after last dose

  10. CogScreen Symbol Digit Coding Test: Response Accuracy (percentage of correct responses)

    Time frame: Approximately 9 hours after last dose

  11. CogScreen Symbol Digit Coding Test: Standard Deviation of Reaction Time

    Time frame: Approximately 9 hours after last dose

  12. Karolinska Sleepiness Scale (KSS) Score

    The KSS measures an individual's subjective level of sleepiness. Participants indicate their level of alertness versus sleepiness according to a 9-point scale, ranging from "extremely alert" to "extremely sleepy - fighting sleep".

    Time frame: Approximately 9 hours after last dose

  13. Participant's self-reported Readiness to Drive

    Prior to driving, the participant will be asked a simple question as to whether they feel safe to drive ("Right now do you feel safe to drive?"). Participant will answer "yes" or "no".

    Time frame: Approximately 9 hours after last dose

  14. Self-report of motivation and appraisal of driving performance using VAS

    Participants will record their response to each question by drawing a vertical line on a 100-mm horizontal, linear VAS printed on paper. For the self-assessment of driving performance, one end of the line is marked "Not Satisfactory" and the other end of the line is marked "Satisfactory". For the motivation item, 1 end of the line is marked "Not Motivated" and the other end is marked "Motivated". Scores on the 100-mm linear scale will be measured to the nearest millimeter from the left with a ruler.

    Time frame: Approximately 9 hours after last dose

07

Study locations

1 site
  • AltaSciences
    Mount-Royal, H3P 3P1, Canada
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Apr 2024, 3 months.

Of 10 phase 1 interventional studies under Hot Flashes, half reached primary completion within 3 months of starting (the median); a quarter within 1 and three quarters within 9. This study's 3 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2023
First posted
Jan 23, 2024
StartActual
Jan 8, 2024
Primary completionActual
Apr 15, 2024
CompletionActual
Apr 15, 2024
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06219902
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 23, 2024
Start date
Jan 8, 2024
Primary completion
Apr 15, 2024
Completion
Apr 15, 2024
Last update
May 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elinzanetant

Start the discussion